6 Results for "

CUTO14

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "CUTO14" in MCE Product Catalog:

12
12 Publications Verification
Cat. No.: HY-135815
CAS No.: 1847461-43-1
Purity:  99.60%
Synonyms: TAK-788; AP32788
Target:  

EGFR

Research Areas:  

Cancer

Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research .
loading...
    loading...
12
12 Publications Verification
Cat. No.: HY-135815A
CAS No.: 2389149-74-8
Purity:  99.83%
Synonyms: TAK-788 succinate; AP32788 succinate
Target:  

EGFR

Research Areas:  

Cancer

Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-157229
CAS No.: 2765525-82-2
Purity:  98.25%
Target:  

EGFR ERK

Research Areas:  

Cancer

STX-721 is an orally active, irreversible, covalent EGFR exon 20 insertion (ex20ins) inhibitor that selectively targets ex20ins-mutant dynamic protein states. STX-721 potently inhibits the kinase activity of EGFR ex20ins mutants (NPG, ASV, SVD). STX-721 inhibits phosphorylation of EGFR (pEGFR Y1068) and downstream ERK (pERK Thr202/Tyr204), and suppresses proliferation of ex20ins-mutant Ba/F3 cells and human NSCLC cell lines (NCI-H2073 ASV KI, CUTO-14 ASV). STX-721 induces tumor regression in EGFR ex20ins-mutant PDX/CDX models. STX-721 can be used for the study of non-small cell lung cancer (NSCLC) harboring EGFR or HER2 ex20ins mutations .
loading...
    loading...
Cat. No.: HY-135815B
CAS No.: 2389149-85-1
Synonyms: TAK-788 mesylate; AP32788 mesylate
Target:  

EGFR

Research Areas:  

Cancer

Mobocertinib (TAK-788) mesylate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib mesylate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib mesylate can be used in NSCLC research .
loading...
    loading...
Cat. No.: HY-135815R
CAS No.: 1847461-43-1
Synonyms: TAK-788 (Standard); AP32788 (Standard)
Research Areas:  

Cancer

Mobocertinib (Standard) is the analytical standard of Mobocertinib. This product is intended for research and analytical applications. Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research .
loading...
    loading...
Cat. No.: HY-135815AR
CAS No.: 2389149-74-8
Synonyms: TAK-788 succinate (Standard); AP32788 succinate (Standard)
Research Areas:  

Cancer

Mobocertinib (succinate) (Standard) is the analytical standard of Mobocertinib (succinate). This product is intended for research and analytical applications. Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research .
loading...
    loading...